The diversity, complexity and volume, as well as privacy and regulatory considerations, necessitate a collaborative and federated approach to life-science data. For scientists to find and share data across Europe and world-wide, ELIXIR needs to continuously develop and connect its services. The international ecosystem provided by ELIXIR – with 220 institutes in 23 Nodes, connecting hundreds of bioinformatics services – is globally unique and a competitive advantage for European research. Through our national Nodes ELIXIR has the geographical spread, service portfolio and expertise to fulfil our ambition that every European project uses FAIR data based on common standards, tools and services. The initial operational phase of ELIXIR, supported by the H2020 ELIXIR-EXCELERATE project, focussed on the coordination and delivery of bioinformatics services from national Nodes. This lay the foundation for a coordinated European infrastructure. ELIXIR-CONVERGE will build on these achievements to deliver another critical component: the provisioning, across Europe, of distributed local support for data management based on a toolkit for researchers that enables lifecycle management for their research data according to international standards. ELIXIR-CONVERGE will develop the national operations of such a distributed research infrastructure to drive good data management, reproducibility and reuse in a heterogeneous funding landscape. Over 36 months and with partners from our 23 Nodes, ELIXIR-CONVERGE takes the next step to realise a European data federation where interconnected national operations, strategically managed via national research infrastructure roadmaps, allow users to extract knowledge from life science’s large, diverse and distributed datasets. By connecting ELIXIR Nodes to provide FAIR data management as a service, ELIXIR-CONVERGE will build national capacity and create a blueprint for operating sustainable Nodes in distributed research infrastructures.

The ISIDORe consortium, made of the capacities of European ESFRI infrastructures and coordinated networks, proposes to assemble the largest and most diverse research and service providing instrument to study infectious diseases in Europe, from structural biology to clinical trials. Giving scientists access to the whole extent of our state of the art facilities, cutting edge services, advanced equipment and expertise, in an integrated way and with a common goal, will enable or accelerate the generation of new knowledge and intervention tools to ultimately help control SARS CoV 2 in particular, and epidemic prone pathogens in general, while avoiding fragmentation and duplication among European initiatives. Such a global and interdisciplinary approach is meant to allow the implementation of user projects that are larger, more ambitious and more impactful than the EU supported transnational activities that the consortium is used to run. Our proposition is ambitious but achievable in a timely fashion due to the relevance and previous experience of the partners that we have gathered and that have complementary fields of expertise, which addresses the need for an interdisciplinary effort. Leveraging all these existing strengths to develop synergies will create an additional value and enhance Europe capacity for controlling emerging or re emerging and epidemic infectious diseases, starting with the COVID 19 pandemic. Such a global and coordinated approach is consistent with the recommendations of the One Health concept and necessary to make significant contributions to solving complex societal problems like epidemics and pandemics.

Metabolic diseases are a burden on the European population and health care system. It is increasingly recognised that individual differences with respect to history, lifestyle, and genetic make-up affect disease progression and treatment response. A Systems Medicine approach, based on computational models fed with individual patient data, has the potential to provide the basis for a personalised diagnosis and treatment strategy. The PoLiMeR consortium (Polymers in the Liver: Metabolism and Regulation) has identified the inherited, liver-related diseases of glycogen and lipid metabolism as the ideal starting point for innovative research training in personalised ‘Systems Medicine’. Our perspective opens possibilities for the application of novel drugs and diagnostic tools to a range of both rare and frequent diseases. To advance diagnostics and treatment of metabolic diseases beyond the state-of-the art, a new generation of scientists is needed. The complexity of the metabolic network and its aberrant behaviour in disease require experts with a deep knowledge and understanding of Systems Medicine approaches. The lack of truly interdisciplinary researchers, trained in the three ‘pillars of Systems Medicine’ - experimental, computational and clinical research - severely hampers progress in this field. PoLiMeR aims to fill this gap and brings together clinical, academic, and industrial experts on inherited metabolic diseases, computational modelling of the entire human metabolism, organ-on-chip technology, and detailed metabolic profiling. Our mission is to train our Early Stage Researchers (ESRs) to become dedicated Systems-Medicine experts, who can seamlessly collaborate between computational and wet-lab environments, and between clinical, academic, and industrial environments. This training will enable them to become the future leaders in the field and eventually make the difference for the patients.